Sign in

aleksanderkrag.bsky.social

@aleksanderkrag.bsky.social
319 followers 12 following 12 posts
PostsRepliesMedia
aleksanderkrag.bsky.social @aleksanderkrag.bsky.social · 16/07/2025
To Screen—or not to screen for for advanced steatotic liver disease that’s the question? Our new @lancetgastrohep.bsky.social review re-examines Wilson & Jungner (1968), weighs today’s evidence, and proposes 2025 screening criteria @Stine Johansen authors.elsevier.com/c/1lRV98nByr...
130
Reposted by @aleksanderkrag.bsky.social
The Lancet Gastroenterology & Hepatology @lancetgastrohep.bsky.social · 16/07/2025
New Review - Screening for advanced steatotic liver disease www.thelancet.com/journals/lan... #LiverSky #MedSky @aleksanderkrag.bsky.social
thelancet.com
Screening for advanced steatotic liver disease
Steatotic liver disease often progresses asymptomatically, with the risk of advancing to cirrhosis and liver cancer. Early detection of advanced liver disease through screening presents an opportunity...
044
Reposted by @aleksanderkrag.bsky.social
Nature Reviews Gastroenterology & Hepatology @natrevgastrohep.nature.com · 31/03/2025
APRIL ISSUE | Our Featured PERSPECTIVE is on "The steatotic liver disease burden paradox: unravelling the key role of alcohol" www.nature.com/articles/s41... #Liversky
Fig. 4: The bidirectional linking of factors that predispose to steatotic liver disease.
042
Reposted by @aleksanderkrag.bsky.social
Nature Reviews Gastroenterology & Hepatology @natrevgastrohep.nature.com · 31/03/2025
Our APRIL ISSUE is live! Steatotic liver disease and alcohol, disorders of gut–brain interaction, coeliac disease, advanced chronic liver disease, and much more! www.nature.com/nrgastro/vol...
Steatotic liver disease burden paradox, inspired by the Perspective on p281.
4135
aleksanderkrag.bsky.social @aleksanderkrag.bsky.social · 25/04/2025
🧪 New findings published in @jhepatology.bsky.social JHEP reports benchmarking several biomarkers and combinations hereof show soluble TREM2, PRO-C3 & HOMA-IR effectively reflect histological disease activity in MASLD/MASH patients in response to treatment.   doi.org/10.1016/j.jh...
010
aleksanderkrag.bsky.social @aleksanderkrag.bsky.social · 16/04/2025
Why do some patients remain healthy while others develop severe liver complications despite having the exact same genetic mutation in Alpha-1 Antitrypsin Deficiency?   Proud of being part of this project - Deep Visual Proteomics at single cell level 👉in @nature.com   www.nature.com/articles/s41...
041
aleksanderkrag.bsky.social @aleksanderkrag.bsky.social · 14/04/2025
Check out the “Steatotic Liver Disease Burden Paradox “ pubmed.ncbi.nlm.nih.gov/39639157/
010
Reposted by @aleksanderkrag.bsky.social
Mads Israelsen @israelsenm.bsky.social · 08/04/2025
Our newdata show 38% of individuals with SLD are reclassified over 2 years ‼️ Over 60% with MetALD/ALD and 38% with MASLD change subclass. This highlights that alcohol use and metabolic risk need regular reassessment, incl. for clinical trial eligibility 🧐 Link: www.cghjournal.org/article/S154...
cghjournal.org
Steatotic liver disease classification is dynamic, affecting clinical trial eligibility and subclass-specific treatments
Steatotic liver disease (SLD) includes the subclasses metabolic-dysfunction associated steatotic liver disease (MASLD), metabolic and alcohol-related liver disease (MetALD) and alcohol-related liver d...
181
Reposted by @aleksanderkrag.bsky.social
EASL @easlnews.bsky.social · 05/02/2025
In today’s #readoftheweek📚 learn why accurate quantification of alcohol intake is crucial in the clinical phenotyping of patients with #steatoticliverdisease & when designing clinical trials. Read now: www.jhep-reports.eu/article/S258... 🙏 @aleksanderkrag.bsky.social @majathiele.bsky.social et al.
042
aleksanderkrag.bsky.social @aleksanderkrag.bsky.social · 31/01/2025
#EASL Studio season 8 starts next week, we will discuss Steatotic Liver Disease - how the current breakthroughs will transform clinical practice. Want to stay updated join us.! easl.eu/easl-studio-...
052
Reposted by @aleksanderkrag.bsky.social
Mads Israelsen @israelsenm.bsky.social · 29/01/2025
AlbTrial Update 🏥 70 out of 240 included But what is AlbTrial? AlbTrial is one of the most ambitious RCTs in the field of decompensated cirrhosis. 🔗 bmjopen.bmj.com/content/bmjo... 🧵below Annual General Assembly in MicrobPredict #liversky #cirrhosis
161
Reposted by @aleksanderkrag.bsky.social
Rob Brierley @robbrierley.bsky.social · 22/01/2025
What impact do reporting discrepancies in alcohol intake have on the estimated prevalence of MetALD and alcohol-related liver disease? @aleksanderkrag.bsky.social and colleagues discuss… www.thelancet.com/journals/lan... #GastroSky #MedSky
thelancet.com
Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALD
For several decades, the prevalence of steatotic liver disease (SLD) has been steadily increasing.1 Alterations in hepatic lipid metabolism, causing steatosis, can result from several factors predomin...
092
aleksanderkrag.bsky.social @aleksanderkrag.bsky.social · 22/01/2025
Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALD - MASLD VS MetALD/ALD is not 10:1 - more likely 1:1😳 - The Lancet Gastroenterology & Hepatology www.thelancet.com/journals/lan...
010
aleksanderkrag.bsky.social @aleksanderkrag.bsky.social · 16/01/2025
Joined a great meeting in Helsinki recently and had the pleasure of seeing but not understanding the new nomenclature of Steatotic liver disease in Finnish😀
030
Reposted by @aleksanderkrag.bsky.social
EASL @easlnews.bsky.social · 15/01/2025
2025 is the perfect year to take your career to the next level🚀 There are also 6 positions to fill in the EASL Scientific Committee, Policy Public Health and Advocacy Committee, Ethics and Compliance Committee and Nurses & AHPs Task Force. Apply by 20 January: easl.eu/leadership25 #LiverSky
0125
Reposted by @aleksanderkrag.bsky.social
Tom Hemming Karlsen @tomhemmingk.bsky.social · 10/12/2024
Two days of finalizing the narrative and recommendations of the second EASL @thelancet.bsky.social Commission in Geneva. Now we write the report! @aleksanderkrag.bsky.social
0113
aleksanderkrag.bsky.social @aleksanderkrag.bsky.social · 13/12/2024
EASL Governing Board meeting - working for the community❤️ 👉SLD and LCS summits 👉EASL schools / what and where? 👉EiC @JHepatology @JHEP_Reports new initiatives🤩 👉 X vs @bluesky ? 👉AI Task Force 👉#EASLCongress 2025 Amsterdam 👉Register grants 👉Global collaboration
0104
aleksanderkrag.bsky.social @aleksanderkrag.bsky.social · 07/12/2024
@EASL @AASLD MASTERCLASS in beautiful Savannah ❤️ Gathering of next generation of leaders in hepatology🤩🤩 👉team science 👉building a team Networking
081
aleksanderkrag.bsky.social @aleksanderkrag.bsky.social · 05/12/2024
Ever heard about the “Steatotic Liver Disease burden paradox”? Check it out 👇👇👇 Perspective in @natureportfolio.bsky.social rdcu.be/d2wcV
010
aleksanderkrag.bsky.social @aleksanderkrag.bsky.social · 30/11/2024
Remember deadline for abstract EASLCongress 2025 in Amsterdam December 3rd !!
000
aleksanderkrag.bsky.social @aleksanderkrag.bsky.social · 23/11/2024
After a successful #TLM24 AASLD in San Diego - thanks Ray Kim and Paul Kwo for a fantastic hospitality at @stanfordpress.bsky.social
010